Form 8-K - Current report:
SEC Accession No. 0001193125-26-249951
Filing Date
2026-06-01
Accepted
2026-06-01 08:51:21
Documents
13
Period of Report
2026-05-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d24037d8k.htm   iXBRL 8-K 32809
2 EX-99.1 d24037dex991.htm EX-99.1 21245
6 GRAPHIC g24037g0601080555279.jpg GRAPHIC 5650
  Complete submission text file 0001193125-26-249951.txt   183874

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20260531.xsd EX-101.SCH 3173
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20260531_lab.xml EX-101.LAB 17232
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20260531_pre.xml EX-101.PRE 10807
16 EXTRACTED XBRL INSTANCE DOCUMENT d24037d8k_htm.xml XML 3507
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 261047513
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)